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higher than that of the ﬁrst visit (p < 0.000). We tested the null that the coefﬁcient 
on the number of visit is equal to zero. We rejected the null hypothesis that the coef-
ﬁcient on the number of visits dummy variable is equal to zero (p < 0.000). CONCLU-
SIONS: Our study ﬁnds that return visits are associated with higher patient satisfaction 
than ﬁrst visit. Furthermore, the dummy variable of the number of visit explains 
patient satisfaction score well.
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OBJECTIVES: The FDA Guidance on the development and use of Patient Reported 
Outcome (PRO) instruments emphasizes the need to establish content validity for the 
concepts addressed by the PRO items. Content validity is the relationship between an 
instrument’s content and the construct it intends to measure. This paper presents eight 
key points of criteria for supporting evidences of content validity for PRO instruments. 
METHODS: Language is the primary means of patient recognition and expression of 
concepts. Concept relevance is assessed by qualitative analysis. A Concept Elicitation 
process is used to describe the relationship between concepts and patient experience. 
Patient comprehension of a concept is evaluated through cognitive interviews. The 
design of interviews and treatment of results must focus on speciﬁc criteria in order 
to support content validity of the PRO. RESULTS: The eight key criteria required to 
support PRO content validity are: (1) concepts are relevant to the patient experience 
with their condition; (2) qualitative data collection has been conducted to the point 
of “saturation of concept” (3) concepts are presented in the langua ge of the patients; 
(4) the appropriate aspect of the concept is being evaluated; (5) the presentation 
of the concept in a PRO can be properly comprehended by patients; (6) response 
options are meaningful and clear; (7) the recall period is appropriate to the patient 
experience of their condition; and (8) the concepts and language used in the PRO are 
adaptable for use in global trials. This paper presents examples of data collection, and 
documentation for each criterion. CONCLUSIONS: Evidences of content validity are 
can only be provided by qualitative data. The qualitative interview process may vary 
in speciﬁc methods but should adhere to consistent objectives, and should cover at 
least eight key evidences in order to provide adequate support for content validity of 
a PRO.
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OBJECTIVES: An algorithm was recently developed to predict median US population 
preferences for EQ-5D health states. The primary objective of this study was to 
provide evidence regarding the estimation efﬁciency of the median-based EQ-5D index 
relative to the existing mean-based index. A secondary objective was to evaluate the 
sensitivity of ﬁndings to the application of robust statistical procedures. METHODS: 
Data were taken from the 2002–2003 Medical Expenditure Panel Survey. Adult survey 
participants completed the EQ-5D and 12-item Short-Form Health Survey (SF-12); 
rated their physical and mental health; and reported the presence of chronic condi-
tions. Associations of mean- and median-based EQ-5D index scores with health status 
measures and chronic conditions were estimated using least squares (LS) and rank (R) 
regression. Associations of changes in index scores with changes in health status 
measures were similarly estimated. For each set of analyses, a relative efﬁciency (RE) 
statistic was derived as the ratio of model F statistics (median-based index/mean-based 
index). RESULTS: RE statistics (LS/R) for associations of index scores with health 
status measures and chronic conditions were as follows: SF-12 mental summary, 
0.50/1.35; SF-12 physical summary, 0.40/0.75; mental health rating, 0.63/1.10; physi-
cal health rating, 0.54/0.99; angina, 0.55/0.89; arthritis, 0.50/0.88; asthma, 0.77/0.98; 
coronary heart disease, 0.54/0.91; diabetes, 0.60/0.95; emphysema, 0.65/1.03; hearing 
problems, 0.50/0.98; myocardial infarction, 0.51/0.97; stroke, 0.66/1.00; and visual 
problems, 0.65/1.03. RE statistics (LS/R) for associations of index score changes with 
changes in SF-12 physical and mental summaries were 0.63/0.89 and 0.59/1.17, 
respectively. CONCLUSIONS: Parametric analyses exhibited reduced power when 
applied to the median-based index scores. However, robust procedures suffered from 
minimal efﬁciency losses and exhibited efﬁciency gains when used to analyze associa-
tions of index scores with mental health measures. These ﬁndings reﬂect the difference 
in skewness between the mean- and median-based index scores, which can be attrib-
uted to the difference in score ranges.
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OBJECTIVES: The reproducibility (kappa) and accuracy (sensitivity/speciﬁcity: SN/SP) 
of diagnostic tests has often been reported. However, both values are discussed sepa-
rately, even when simultaneously determined. Because good reproducibility is the 
premise for good accuracy, integrated interpretation of both is required. The present 
study investigates the relationship between kappa and measured SN/SP by Monte-
Carlo simulation given true accuracy and measurement error. METHODS: We 
assumed diseased and non-diseased populations with test values that are normally 
distributed with different means and the same standard deviation. True SN/SP given by 
a threshold value is decreased by the measurement error that is also normally distrib-
uted and this leads to measured SN/SP. We assumed that sensitivity equals speciﬁcity 
for convenience. Two measurements can generate kappa statistics. We simulated this 
process using Monte-Carlo simulation. The true mean difference of both the population 
and the standard deviation of measurement error was changed for a variety of combina-
tions then kappa and measured SN/SP were compared. We assumed a total population 
of 100,000, and disease prevalences of 10% and 50%. Simulation was done in STATA 
10/SE. RESULTS: Disease prevalence did not substantially affect the results, so only the 
results for 10% prevalence are described. At a true SN/SP of 93.1% and kappa values 
of 0.75, 0.5 and 0.25, measured SN/SP decreased to 91.3%, 86.1% and 77.1%, respec-
tively. At a true SN/SP of 68.9% and kappa values of 0.75, 0.5, 0.25, measured SN/SP 
decreased to 68.3%, 66.0%, 61.7%, respectively. Now we know measured SN/SP can 
substantially or not improve so much when kappa improves, depending on the combi-
nation of kappa and measured SN/SP. CONCLUSIONS: The relationship between 
kappa and SN/SP allows the integrated interpretation of both, and indicates how much 
accuracy can be improved by improving reproducibility.
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OBJECTIVES: Difference-in-difference (DID) and propensity score matching (PSM) 
methods are two ways of evaluating the effect of changes in policies inﬂuencing drug 
prescribing or medications. The objective of this study is to compare and contrast the 
strengths and weakness and different types of information provided by the DID and 
PSM methods in the context of determining the impact of an insurance plan restriction 
on binary health care utilization outcomes. Adult patients diagnosed with diagnosis 
A were selected from MarketScan® Commercial Database (2005–2007), a large claims 
data form persons with employ-based insurance. METHODS: The DID analysis was 
implemented by a GEE regression with logit link, binomial variance function, and 
exchangeable correlation structure on panel data with pre- and post-restriction period. 
The dependent variables included inpatient hospitalization, ER visit, use of alternative 
drug B, and use of alternative drug C. The key independent variables included an 
indicator for plan restriction, an indicator for pre- or post- restriction period, and an 
interaction term between them. Demographic and clinical characteristics were included 
as covariates. The odds ratios (OR) of the interaction terms were considered as the 
DID estimates. In the PSM method, patients in restricted and unrestricted plans were 
propensity score matched based on pre-implementation characteristics, followed by 
logistic regressions. RESULTS: Without controlling for any covariate, the restriction 
effects were non-signiﬁcant on all outcomes using DID analysis. The restriction effects 
were signiﬁcant for ER visit and hospitalization using PSM. When all characteristics 
were controlled, the restriction effects were non-signiﬁcant in both methods, except 
the outcome of drug B use. CONCLUSIONS: DID and PSM- based methods may 
produce different estimates. Neither method can fully control all potential confound-
ers. Compared with the PSM method, DID method uses same individual as the control, 
but is restricted to studies when pre- and post-event data are available.
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OBJECTIVES: To review important statistical methods used in health economics. 
BACKGROUND: During two decades in health economics at Novartis Pharmaceuti-
cals, statistician Doug Gause regularly presented friendly one-page illustrations of 
statistical concepts in health economics. Thirty of these “Analysis Notes” are presented 
on this poster, along with a magnifying glass for easier viewing. ANALYSIS NOTES: 
Making inferences: Conﬁdence interval estimation instead of hypothesis testing, and 
bootstrapping to avoid assumptions. Analyzing costs: Two-part GLM models instead 
of transformations. Measuring compliance: Avoiding adherence bias in calculating 
MPR. Competing risks of discontinuing, adding, switching, or remaining on drug. 
Data visualization: Regression trees, drug-o-grams, mosaic plots, parallel coordinate 
plots, and sequence plots to visualize patterns. (Lets reserve pie charts for the Baker’s 
Convention !) Covariate adjustment: Marginal means/IPTW, confounders vs. collid-
ers, instrument variables, and time dependent covariates to incorporate changes over 
time. Historical data: Bayesian analysis for bias adjusting, and meta-analysis to incor-
porate results from multiple studies. Avoiding pitfalls: Be aware of the “individual-
ized” fallacy and the “ecological” fallacy. Differential follow-up: Person-time and 
survival analysis to accommodate censoring. Predictive modeling: Nearest neighbor 
vs. recursive partitioning vs. neural networks. Project planning: Sample size to han-
dling multiplicity. Clustered/longitudinal data: Random effects models to account for 
correlated observations from the same physician or repeated measurements from the 
same patient. Cost-effectiveness: Angles instead of ratios, and incremental net beneﬁt 
to handle multiple effectiveness measures. Heterogeneous data: Quantile and polyto-
mous regression to compare different MPR distributions. CONCLUSIONS: Statistics 
